AGRX - アジャイル・セラピュ―ティクス (Agile Therapeutics Inc.) アジャイル・セラピュ―ティクス

 AGRXのチャート


 AGRXの企業情報

symbol AGRx
会社名 Agile Therapeutics Inc (アジャイル・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アジャイル・セラピューティクス(Agile Therapeutics Inc.)は女性の健康向けスペシャリティ医薬品企業。同社は、新規処方避妊製品の開発と商業化に焦点を当てる。同社の製品候補は、利便性を提供し、コンプライアンスを促進する避妊オプションを女性に提供するために設計される。同社のリード製品候補の「Twirla」はまた「AG200-15」として知られ、フェーズⅢ臨床開発にある週一回の処方避妊パッチである。「Twirla」は、利用可能なパッチを上回る利点を提供するように設計され、パッチの密着性・安定性と患者の快適性を最適化するように意図される「Skinfusion」という経皮パッチ技術に基づく。「Twirla」は、プロゲスチンの一種の合成ステロイドホルモンであるレボノルゲストレル(LNG)、及び合成エストロゲンである有効成分のエチニルエストラジオール(EE)を含有する複合ホルモン避妊薬(CHC)パッチである。   アジャイル・セラピュ―ティクスは、女性のヘルスケア製品に特化した米国の医薬品開発会社。新規処方避妊製品の開発と商業化に注力する。避妊用の経皮パッチ技術「スキンフュ―ジョン」を研究・開発する。同社の製品候補である避妊パッチ「Twirla(別名AG200-15)」は、避妊を選択する女性に利便性を提供し、迎合性を容易にする。  
本社所在地 101 Poor Farm Road Princeton NJ 08540 USA
代表者氏名 Alfred Altomari アルフレッドアルトマリ
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 609-683-1880
設立年月日 35765
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数
url www.agiletherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/agrx
adr_tso
EBITDA EBITDA(百万ドル) -24.44100
終値(lastsale) 0.46
時価総額(marketcap) 15813571.34
時価総額 時価総額(百万ドル) 24.40790
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 9.46790
当期純利益 当期純利益(百万ドル) -25.51900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Agile Therapeutics Inc revenues was not reported. Net loss decreased 19% to $12.2M. Lower net loss reflects Other Research and Development decrease of 28% to $5.7M (expense) Other General and administrative decrease of 10% to $4M (expense) Interest expense decrease of 34% to $688K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.52 to -$0.36.

 AGRXのテクニカル分析


 AGRXのニュース

   Agile Therapeutics (NASDAQ:AGRX) Posts Earnings Results, Beats Expectations By $0.02 EPS  2021/03/02 12:10:42 Transcript Daily
Agile Therapeutics (NASDAQ:AGRX) announced its quarterly earnings results on Sunday. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.02, MarketWatch Earnings reports. AGRX opened at $3.02 on Tuesday. Agile Therapeutics has a twelve month low of $1.35 and a twelve month high of $3.89. The […]
   Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference  2021/01/04 17:18:30 GlobeNewswire
PRINCETON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced Chairman and…
   Hormonal Contraception Market Analysis by Size, Share, Growth, Trends up to 2026|Merck & Co., Inc., Pfizer, Inc., Agile Therapeutics, Inc.  2020/12/16 07:18:42 OpenPR
A complete study of the global Hormonal Contraception market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of
   Agile Therapeutics Announces Nationwide Commercial Launch and Availability of Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System, a New Non-Daily, Non-Invasive Contraceptive Patch - Stocks News Feed  2020/12/07 12:30:00 Stocks News Feed
Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE) PRINCETON, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the U.S. commercial launch of Twirla® (levonorgestrel and ethinyl estradiol) transdermal system, a new non-daily, non-invasive contraceptive patch. Twirla is… Read More »Agile Therapeutics Announces Nationwide Commercial Launch and Availability of Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System, a New Non-Daily, Non-Invasive Contraceptive Patch
   Agile Therapeutics’ (AGRX) “Buy” Rating Reiterated at Royal Bank of Canada  2020/11/19 06:06:41 Transcript Daily
Royal Bank of Canada reissued their buy rating on shares of Agile Therapeutics (NASDAQ:AGRX) in a research note issued to investors on Monday morning, AnalystRatings.com reports. They currently have a $8.00 price target on the specialty pharmaceutical company’s stock. AGRX has been the topic of a number of other reports. Maxim Group reaffirmed a buy […]
   Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference  2021/01/04 17:18:30 GlobeNewswire
PRINCETON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced Chairman and…
   Hormonal Contraception Market Analysis by Size, Share, Growth, Trends up to 2026|Merck & Co., Inc., Pfizer, Inc., Agile Therapeutics, Inc.  2020/12/16 07:18:42 OpenPR
A complete study of the global Hormonal Contraception market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of
   Agile Therapeutics Announces Nationwide Commercial Launch and Availability of Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System, a New Non-Daily, Non-Invasive Contraceptive Patch - Stocks News Feed  2020/12/07 12:30:00 Stocks News Feed
Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE) PRINCETON, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the U.S. commercial launch of Twirla® (levonorgestrel and ethinyl estradiol) transdermal system, a new non-daily, non-invasive contraceptive patch. Twirla is… Read More »Agile Therapeutics Announces Nationwide Commercial Launch and Availability of Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System, a New Non-Daily, Non-Invasive Contraceptive Patch
   Agile Therapeutics’ (AGRX) “Buy” Rating Reiterated at Royal Bank of Canada  2020/11/19 06:06:41 Transcript Daily
Royal Bank of Canada reissued their buy rating on shares of Agile Therapeutics (NASDAQ:AGRX) in a research note issued to investors on Monday morning, AnalystRatings.com reports. They currently have a $8.00 price target on the specialty pharmaceutical company’s stock. AGRX has been the topic of a number of other reports. Maxim Group reaffirmed a buy […]
   Agile Therapeutics Analyst Valuation and EPS Growth for Stock market Insights & financial analysis  2020/10/26 18:35:00 Stock Market Daily
Agile Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アジャイル・セラピュ―ティクス AGRX Agile Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)